Tesamorelin Ipamorelin blend dosage: Frequently asked questions

Administer at least 3 hours after the last meal in a fasted state to avoid interference from elevated glucose and insulin, which suppress growth hormone secretion through somatostatin upregulation. Morning administration is the second-best timing window after pre-sleep dosing, as endogenous GH secretion naturally peaks 30–60 minutes after waking in most circadian patterns. Avoid administration within 90 minutes of resistance exercise. The exercise-induced GH pulse and exogenous secretagogue administration create overlapping signals that may accelerate receptor desensitization rather than amplifying response.

Discard the vial and do not administer. Peptides left at room temperature for more than 4 hours undergo partial denaturation. The tertiary protein structure required for receptor binding unfolds as hydrogen bonds destabilize at temperatures above 8°C. Visual inspection cannot detect this: the solution remains clear and colorless even when bioactivity has dropped by 40–70%. Refrigerating the vial after the temperature excursion does not reverse denaturation. Administering compromised peptide wastes the dose and introduces measurement error into research outcomes, as the actual administered bioactivity is unknowable.

Rotate injection sites more frequently and reduce injection volume per site. Subcutaneous administration of peptides can cause localized histamine response or lipohypertrophy if the same site is used repeatedly. Ipamorelin specifically has been associated with mild injection site reactions in 5–10% of research applications, typically resolving within 24–48 hours. If swelling persists beyond 72 hours or is accompanied by systemic symptoms (fever, malaise), discontinue administration and investigate potential bacterial contamination. This suggests bacteriostatic water contamination or vial breach, not peptide intolerance.

Increase to 200mcg of each peptide daily and reassess after 10–14 additional days. Individual response variability is significant: somatotroph receptor density, endogenous GHRH secretion baseline, and hepatic IGF-1 synthesis capacity differ across research models. Some models demonstrate maximal response only at 250–300mcg, while others plateau at 150mcg. If no IGF-1 elevation occurs at 300mcg after three weeks, verify peptide storage integrity and reconstitution technique before concluding non-response. Storage errors are far more common than true receptor insensitivity.

Convert milliliters to syringe units using the syringe's unit-to-volume ratio. Standard insulin syringes (U-100) have 100 units per 1mL, so 0.3mL = 30 units. If your calculated injection volume is 0.3mL and you're using a U-100 syringe, draw to the 30-unit mark. For U-50 syringes (50 units per 1mL), 0.3mL = 15 units. Always verify your syringe's unit-to-volume conversion before drawing doses. Using the wrong conversion factor invalidates every subsequent injection.

Sum the total peptide mass regardless of ratio. A 5mg + 5mg blend (10mg total) reconstituted with 2mL produces 5mg/mL concentration. Identical to a 10mg + 5mg blend reconstituted with 3mL. The formula remains: total mass ÷ volume = concentration. If your protocol specifies doses per compound (e.g., 0.5mg Tesamorelin + 0.5mg Ipamorelin), add them to get total dose (1mg), then divide by concentration to get injection volume.

Recalculate concentration using the actual volume added. If you intended 3mL but accidentally added 4mL to a 15mg blend, your actual concentration is 15mg ÷ 4mL = 3.75mg/mL, not 5mg/mL. To deliver a 1.5mg dose at this lower concentration, you now need 0.4mL per injection instead of 0.3mL. Do not attempt to compensate by reducing injection volume. Use the actual concentration and adjust injection volume accordingly. Dilution errors change concentration but do not affect total peptide mass or compound ratio.

Allow 3–5 minutes of passive dissolution with gentle swirling every 60 seconds. Never shake vigorously, as mechanical agitation denatures peptide bonds. If cloudiness or visible particulates persist beyond 5 minutes, the peptide has likely degraded due to temperature excursion during shipping or storage. Properly manufactured and stored lyophilized peptides dissolve completely into clear, colorless solution within 2–3 minutes of bacteriostatic water contact. Cloudiness, precipitation, or color change (yellowing, browning) indicates protein denaturation. Discard the vial and contact your supplier. Injecting denatured peptide solution produces no adverse effects but delivers zero bioactivity, wasting your research cycle.

Measure the actual volume you added, then recalculate concentration using that number. If you intended 2mL but added 3mL to a 10mg vial, your actual concentration is 10mg ÷ 3mL = 3.33mg/mL (3330mcg/mL), not 5mg/mL. Adjust your dose calculation accordingly: for a 500mcg dose, you'd draw (500 ÷ 3330) × 1000 = 15 units instead of 10 units. Do not attempt to remove excess bacteriostatic water from the vial or add more peptide powder. Both introduce contamination risk and measurement error. The solution remains viable as long as you recalculate correctly.

Recalculate using the same formula with your new target dose. If you started at 400mcg total dose (8 units with a 5mg/mL concentration) and want to increase to 600mcg, the new calculation is (600 ÷ 5000) × 1000 = 12 units. Document the dose change date and new unit volume in your protocol records to maintain reproducibility. Dose adjustments should occur no more frequently than every 7–10 days to allow physiological steady-state. GH-mediated metabolic changes take 5–7 days to stabilize after dose modification, so adjusting every 2–3 days creates confounded endpoint data.

Pre-blended vials lock you into a fixed ratio (typically 1:1). If your protocol specifies 500mcg Tesamorelin + 200mcg Ipamorelin, you need separate vials reconstituted independently. Reconstitute each peptide in its own vial, calculate the units required for each target dose separately, then draw from both vials into the same syringe (draw the smaller volume first to minimize dead space loss). This allows complete dose customization but requires tracking two reconstitution calculations and two expiration dates. Researchers exploring Sermorelin or CJC-1295 NO DAC as alternative GHRH analogues often use this independent-vial method for precise dose-response studies.

No. The tesamorelin + ipamorelin blend is designed to mimic nocturnal GH secretion. Morning injections desynchronize the protocol from the body's natural rhythm and suppress endogenous daytime GH pulses. If you miss a nighttime dose, skip it entirely and resume the following evening at standard time. Missing 1–2 doses per month has negligible impact on 12-week IGF-1 outcomes, but morning make-up doses disrupt the circadian alignment that makes this combination effective. Consistency matters more than perfection.

Three possibilities: the peptide is degraded (storage failure), the dose is insufficient for your receptor density, or hepatic IGF-1 conversion is impaired. First, verify storage compliance. Any temperature excursion above 8°C for >4 hours compromises potency. Second, increase dose by 20% (to 1.2mg tesamorelin + 240–360mcg ipamorelin) and retest at week 10. If IGF-1 remains unchanged, consider switching to MK 677, a non-peptide ghrelin mimetic with oral bioavailability that bypasses reconstitution variables. Persistent non-response despite protocol compliance suggests pituitary hyporesponsiveness, which requires endocrine evaluation.

Discard the vial immediately. Cloudiness indicates bacterial contamination or peptide aggregation. Both render the solution unsafe and ineffective. Aggregated peptides cannot bind to receptors and may trigger immune responses. This typically occurs due to temperature excursion (vial left at room temperature >4 hours), contaminated bacteriostatic water, or improper reconstitution technique. If cloudiness appears within 48 hours of mixing, the lyophilised powder was likely compromised during shipping. Contact your supplier for replacement. Legitimate peptide vendors replace visibly degraded product.

Administer the dose anyway. Skipping it disrupts the pulsatile pattern and delays receptor sensitization. The GH pulse will be blunted (expect 30–50% reduced magnitude), but partial stimulation maintains receptor priming. Resume standard timing (2+ hours post-meal) the following night. Do not double-dose to compensate. This elevates GH too high outside the physiological range and triggers glucose intolerance. If meal-timing conflicts occur more than twice weekly, the protocol is incompatible with your schedule and should be adjusted to an earlier injection window or alternate fasting strategy.

Verify caloric intake first. Progressive fat loss requires sustained energy deficit, and metabolic adaptation reduces total daily energy expenditure by 200–400 calories after 12+ weeks of dieting, meaning what was a deficit at week 4 may now be maintenance. If caloric intake is confirmed appropriate and imaging shows no VAT change for 4+ weeks, consider adding a third ipamorelin dose (pre-bed) to extend the nocturnal GH pulse window. Overnight fasting is the longest daily oxidative window, and amplifying GH during this period can restart lipolysis. Alternatively, implement a 5-day-on, 2-day-off tesamorelin cycle to prevent receptor downregulation while maintaining continuous ipamorelin. Limited data supports this approach but the mechanism is sound.

Skip that night's dose entirely and resume your regular schedule the following evening. Do not inject the blend in the morning or midday to 'make up' for a missed dose. Injecting during waking hours suppresses your natural nighttime GH pulse through negative feedback, which compounds the problem. A 2024 study at Johns Hopkins found that subjects who injected tesamorelin at inconsistent times (varying by more than 3 hours night-to-night) showed 43% lower fat loss compared to those maintaining strict timing adherence.

These are transient vasodilatory effects caused by rapid GH release, occurring in 15–25% of users during the first two weeks. Symptoms typically resolve within 10–15 minutes and diminish with continued use as the body adapts. Lying down immediately after injection reduces symptom intensity. If flushing persists beyond 30 minutes or is accompanied by chest tightness or difficulty breathing, discontinue use and consult a medical professional. This may indicate histamine sensitivity or an allergic reaction to the carrier peptide.

Resume at your established dose immediately. Do not attempt 'catch-up' dosing or double doses. Tesamorelin and ipamorelin have no meaningful tissue accumulation (both are cleared within 24 hours), so missed doses represent lost GH pulses but don't create a deficit requiring compensation. The primary risk from inconsistent dosing isn't safety. It's attenuated results. A 26-week protocol with 70% adherence (missing 2 days per week) produces roughly 60% of the visceral fat reduction seen with full adherence, based on pharmacokinetic modelling. If travel or storage constraints will interrupt dosing for >5 days, plan the interruption deliberately rather than sporadic missed doses. Consecutive missed days are less disruptive to receptor sensitivity than random skipped doses throughout the protocol.

Non-response occurs in approximately 8–12% of individuals and suggests either peptide degradation (improper storage, expired product) or GH receptor polymorphisms that reduce sensitivity. Verify storage conditions first: peptides stored above 8°C for more than 48 hours lose 60–80% potency. If storage is confirmed correct, consider increasing the dose by 25% (e.g., from 500mcg to 625mcg total daily) and retest IGF-1 after another four weeks. Persistent non-response warrants genetic testing for GHR variants or consultation with an endocrinologist.